High-signal headlines only - macro events, earnings, M&A, regulatory. Listicles and analyst clickbait filtered out by default. Refreshed hourly.
Even without its metabolic business, management argues Eli Lilly (LLY) would be one of the fastest-growing pharmaceutical companies in the industry. This is not a single-product story. The company's immunology, oncology, and neuroscience medicines collectively grew by 160%, showing the depth of its R&D engine.
Berkshire Hathaway, Eli Lilly and Walmart headline new analyst reports, highlighting growth drivers, opportunities and key risks shaping their outlooks.
Healthcare stocks were higher late Thursday afternoon, with the NYSE Healthcare Index climbing 3.2%
Eli Lilly stock is Thursday's IBD Stock Of The Day as the weight-loss behemoth deepens its focus on gene editing, vaccines and cancer.
WW International (NASDAQ:WW) has integrated its Weight Watchers Med+ offering with Eli Lilly’s (NYSE:LLY) LillyDirect healthcare platform, broadening access to its clinical weight management services for patients using or considering prescription obesity treatments. The collaboration connects LillyDirect users with Weight Watchers’ program, which combines GLP-1 medications with behavioral, nutritional and lifestyle support.
Eli Lilly knows that its GLP-1 windfall comes with an end date, so it is acting now to prepare.
The company cited uncertainty surrounding proposed healthcare and drug-pricing reforms.
Although Moderna has outperformed the broader health care sector over the last 12 months, analysts maintain a cautious stance on the stock’s future outlook.
The shares are up more than 13% this year, and the pharmaceutical company has several other factors that could drive its stock higher.
Lilly’s deal with Ascidian is one of several that the pharma giant has cut within the realm of genetic medicines.
Eli Lilly is far from a one-trick pony.
Drugmaker expands genetic medicine push with Ascidian partnership targeting rare kidney diseases.
Eli Lilly (NYSE:LLY) reported Phase 3 LIBRETTO-432 data showing Retevmo (selpercatinib) cut the risk of recurrence or death in early-stage RET fusion-positive non-small cell lung cancer. The results position Retevmo as a potential new adjuvant standard of care for this genetically defined group of lung cancer patients. Separately, Lilly released encouraging first-in-human data for VERVE-102, a gene-editing therapy targeting cardiovascular disease. Eli Lilly enters this news cycle with a...
Can any company pose a serious challenge to Eli Lilly in the weight-loss market?
Eli Lilly and Co. announced separate licensing and research agreements with South Korea-based Hanmi Pharm and China-based Haisco Pharmaceutical Group, expanding its access to new drug candidates and discovery programs. The deals come as investors also evaluate positive Phase 3...
SpaceX looks like a rocket, but don't fly too close to the sun. Here's why Eli Lilly is likely a better stock to own.
Over recent months, a striking pattern has emerged: major capital allocators are positioning around AI-driven biology and longevity. According to a Polymarket post on X, Coinbase (NASDAQ:COIN) founder Brian Armstrong’s longevity startup NewLimit has tripled in value to $3.1 billion. That post sparked a viral reply thread from podcast host Mgoes (@m_goes_distance), cataloging billionaire and ... Move Over AI: Jeff Bezos and NVIDIA Are Quietly Backing a New Breakthrough Industry
Eli Lilly (NYSE:LLY) just grew revenue 55.5% in a single quarter while raising full-year guidance to $82 billion to $85 billion. Mounjaro and Zepbound combined for $12.8 billion in Q1 alone. Yet shares are up just 1.11% year to date, sitting at $1,082.92. Can LLY reach $1,500 a share by 2028? Why Lilly Shares Have ... Where Will Eli Lilly Stock be In 2028?
Ocugen's three ocular gene therapy programs could deliver trial data, filings, and potential BLA milestones through 2028 as key readouts approach.
ABBV wins EU approval for Aquipta for acute migraine treatment in adults, adding a second approved indication in migraine.
The agreement gives Lilly exclusive rights to Ascidian's RNA exon-editing technology, which repairs faulty genes without altering a patient's DNA
Eli Lilly signed a collaboration and licensing agreement worth up to $1.9 billion with Ascidian Therapeutics to research and develop kidney-disease treatments.
Wells Fargo’s chief agriculture economist Dr. Michael Swanson told Bloomberg Businessweek on May 29 that GLP-1 weight-loss drugs (Ozempic, Wegovy, Mounjaro, Zepbound) will eventually match statins at roughly 90 million prescriptions, calling the trend “here to stay” because it’s prescribed, not faddish. So this is the next 90-million-customer industry, sitting in plain sight while everyone ... 5 Stocks Set to Cash in on The Next 90-Million Customer Industry. (It’s Not AI)
The anti-aging biotech has secured one of the year’s biggest venture fundings to bring its first drug into testing. Elsewhere, Lilly nabbed a “GLP-2” obesity drug and Praxis shares tumbled.
The pharmaceutical company's most promising drug candidate has some potential advantages over its rivals.
Memory chipmaker Micron Technology leapfrogged South Korean rival SK Hynix to become the 12th most-valuable company in the world, in a rally that has more than tripled the stock this year. Shares jumped another 7.5% Monday to $1,044, lifting the...
We use Google Analytics to count anonymous page views and understand which content gets read. No ads, no profiles. Decline keeps you on cookieless mode. Details.
